иНГЛТ2 при ХСНнФВ: почему бездействуем?

It takes approximately 10-20 years for new clinical guidelines to become routine clinical practice. How can therapeutic inertia be overcome? Due to the increasing mortality rate from cardiovascular diseases, to which chronic heart failure makes a significant contribution, the rapid adoption of new classes of drugs and the use of quadruple therapy for the treatment of CHF is essential. The authors will examine in detail the feasibility of actively implementing clinical guidelines for the treatment of CHF in clinical practice, as well as the specifics of treatment algorithms and management strategies for patients with CHF. Speakers: Yuri Mikhailovich Lopatin - Head of the Department of Cardiology, Cardiovascular, and Thoracic Surgery, Institute of Continuous Medical and Pharmaceutical Education, Volgograd State Medical University, Ministry of Health of the Russian Federation, MD, Professor, Honored Doctor of the Russian Federation, Member of the Presidium of the Board of the Russian Society of Cardiology Sergey Vladimirovich Nedogoda - Vice-Rector for Regional Healthcare Development and Clinical Work, Head of the Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education, Volgograd State Medical University, Ministry of Health of the Russian Federation, MD, Professor, Honored Doctor of the Russian Federation, Vice President of the Russian Society of Cardiology, Member of the Presidium of the Board of the Russian Society of Cardiology Program: 2:00 PM - 3:15 PM - Lecture: "IGLT2 in CHF: Why Are We Inactive?" 15:15 - 15:30 - Discussion, Q&A. Sponsored by AstraZeneca. CME points will not be awarded. 0:00 Start Screen 1:02 Introduction 2:10 Reasons for and Ways to Overcome Clinical Inertia 9:31 What Underlies the Change in the Approach to HFrEF Treatment According to the 2021 Clinical Guidelines 16:15 Rationale for SGLT2 inhibitors in Patients with CHF and Without Diabetes: Results of the DAPA-HF and EMPEROR Trials 25:33 NICE 2021 Study: Pharmacoeconomic Efficacy of Dapagliflozin 34:25 Quadruple Therapy: Concurrent or Sequential Administration? Drug Properties and Characteristics 51:57 Will Dapagliflozin Reduce HF Symptoms? Is it Possible to Prescribe SGLT2 Inhibitors Without an Endocrinologist's Consultation? 1:10:08 At what eGFR level can dapagliflozin be prescribed for HFrEF? 1:14:20 Answers to questions. Is empagliflozin recommended for the treatment of HF with preserved ejection fraction combined with persistent AF? Can it reduce the frequency of AF paroxysms? Diuretic therapy in this regimen: Where? A patient with CHF stage 3 (edema of the lower extremities, hydrothorax) where do we begin? Why don't you talk about the need to return fluid to the vascular bed and how to do this? 1:18:20 Can these drugs be prescribed to a patient with CKD stage 4 (SCF 27-28 ml/min)? 1:20:30 It's important to remember that the same disease, but in two different patients, requires very different treatments! Polypharmacy is a "limiting" factor in the treatment of patients with CHF. What is your opinion? 1:24:18 Please tell me when new Russian guidelines for heart failure treatment will be released?